These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37002576)
1. Exogenous hydrogen sulfide (H Cui X; Liu R; Duan L; Zhang Q; Cao D; Zhang A Biomed Pharmacother; 2023 May; 161():114488. PubMed ID: 37002576 [TBL] [Abstract][Full Text] [Related]
2. A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression. Youness RA; Assal RA; Abdel Motaal A; Gad MZ Nitric Oxide; 2018 Nov; 80():12-23. PubMed ID: 30081213 [TBL] [Abstract][Full Text] [Related]
3. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. Li H; Xu F; Gao G; Gao X; Wu B; Zheng C; Wang P; Li Z; Hua H; Li D Redox Biol; 2020 Jul; 34():101564. PubMed ID: 32403079 [TBL] [Abstract][Full Text] [Related]
4. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418 [TBL] [Abstract][Full Text] [Related]
5. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining. Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373 [TBL] [Abstract][Full Text] [Related]
6. GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer. Peng L; Song Z; Chen D; Linghu R; Wang Y; Zhang X; Kou X; Yang J; Jiao S Biomed Pharmacother; 2016 Dec; 84():1568-1574. PubMed ID: 27829549 [TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing. Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321 [TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis. Zhai Q; Li H; Sun L; Yuan Y; Wang X Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620 [TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer. Peng C; Ma W; Xia W; Zheng W Mol Med Rep; 2017 Mar; 15(3):1087-1094. PubMed ID: 28075450 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis. Yuan Q; Zheng L; Liao Y; Wu G World J Surg Oncol; 2021 Mar; 19(1):86. PubMed ID: 33757543 [TBL] [Abstract][Full Text] [Related]
11. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988 [TBL] [Abstract][Full Text] [Related]
12. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer. Naorem LD; Muthaiyan M; Venkatesan A J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816 [TBL] [Abstract][Full Text] [Related]
13. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447 [TBL] [Abstract][Full Text] [Related]
14. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567 [TBL] [Abstract][Full Text] [Related]
15. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation. Velloso FJ; Campos AR; Sogayar MC; Correa RG BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886 [TBL] [Abstract][Full Text] [Related]
16. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355 [TBL] [Abstract][Full Text] [Related]
17. Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology. Liu N; Wang X; Zhu Z; Li D; Lv X; Chen Y; Xie H; Guo Z; Song D Aging (Albany NY); 2021 Oct; 13(20):23702-23725. PubMed ID: 34686627 [TBL] [Abstract][Full Text] [Related]
18. Targeting Wnt/β-catenin signaling pathway in triple-negative breast cancer by benzylic organotrisulfides: Contribution of the released hydrogen sulfide towards potent anti-cancer activity. Bhattacherjee D; Raina K; Mandal TK; Thummer RP; Bhabak KP Free Radic Biol Med; 2022 Oct; 191():82-96. PubMed ID: 36038037 [TBL] [Abstract][Full Text] [Related]
19. Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses. Xiao X; Zhang Z; Luo R; Peng R; Sun Y; Wang J; Chen X Oncol Lett; 2021 May; 21(5):363. PubMed ID: 33747220 [TBL] [Abstract][Full Text] [Related]
20. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Guo GC; Wang JX; Han ML; Zhang LP; Li L Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]